Lupus Foundation of America4d
Fate Therapeutics Announces Promising Initial Data from FT819 Phase 1 Study for Moderate to Severe Systemic Lupus Erythematosus
Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...
bovnews6d
Why Did Fate Therapeutics Inc (FATE) Stock See -28.80% Plunge in the Last 90 Days?
On Monday, Fate Therapeutics Inc (FATE) stock saw a modest uptick, ending the day at $2.72 which represents a slight increase of $0.07 or 2.64% from the prior close of $2.65. The stock opened at $ and ...
Nasdaq4d
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Fate Therapeutics (FATE). Shares have added about 0.5% in that time frame, underperforming the S&P 500. Will the recent positive trend ...
bovnews2d
Fate Therapeutics Inc (FATE) Stock Rated Neutral by BofA Securities
Fate Therapeutics Inc (FATE) stock saw a decline, ending the day at $1.83 which represents a decrease of $-0.09 or -4.69% from the prior close of $1.92. The stock opened at $1.97 and touched a low of ...
Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $6.75
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has received an average recommendation of “Hold” from the ten ratings ...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to ...
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 24.7% in the third quarter, according to the company in its most recent ...